SEARCH

SEARCH BY CITATION

References

  • Azambuja, E., Fleck, J.F., Batista, R.G. & Menna Barreto, S.S. (2005) Bleomycin lung toxicity: who are the patients with increased risk? Pulmonary Pharmacology & Therapeutics, 18, 363366.
  • Ballova, V., Ruffer, J.U., Haverkamp, H., Pfistner, B., Muller-Hermelink, H.K., Duhmke, E., Worst, P., Wilhelmy, M., Naumann, R., Hentrich, M., Eich, H.T., Josting, A., Loffler, M., Diehl, V. & Engert, A. (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Annals of Oncology, 16, 124131.
  • Brenner, H., Gondos, A. & Pulte, D. (2008) Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood, 111, 29772983.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235242.
  • Enblad, G., Glimelius, B. & Sundstrom, C. (1991) Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Annals of Oncology, 2, 297302.
  • Enblad, G., Sandvej, K., Sundstrom, C., Pallesen, G. & Glimelius, B. (1999) Epstein–Barr virus distribution in Hodgkin's disease in an unselected Swedish population. Acta Oncologica, 38, 425429.
  • Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Duhmke, E., Muller-Hermelink, K. & Diehl, V. (2005) Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology, 23, 50525060.
  • Erdkamp, F.L., Breed, W.P., Bosch, L.J., Wijnen, J.T. & Blijham, G.B. (1992) Hodgkin disease in the elderly. A registry-based analysis. Cancer, 70, 830834.
  • Evens, A.M., Cilley, J., Ortiz, T., Gounder, M., Hou, N., Rademaker, A., Miyata, S., Catsaros, K., Augustyniak, C., Bennett, C.L., Tallman, M.S., Variakojis, D., Winter, J.N. & Gordon, L.I. (2007) G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. British Journal of Haematology, 137, 545552.
  • Evens, A.M., Sweetenham, J.W. & Horning, S.J. (2008) Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park), 22, 13691379.
  • Evens, A.M., Helenowski, I., Ramsdale, E., Nabhan, C., Karmali, R., Hanson, B., Parsons, B., Smith, S., Larsen, A., McKoy, J.M., Jovanovic, B., Gregory, S., Gordon, L.I. & Smith, S.M. (2012) A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood, 119, 692695.
  • Gandhi, M.K., Tellam, J.T. & Khanna, R. (2004) Epstein–Barr virus-associated Hodgkin's lymphoma. British Journal of Haematology, 125, 267281.
  • Gordon, L.I., Hong, F., Fisher, R.I., Bartlett, N.L., Connors, J.M., Gascoyne, R.D., Wagner, H., Stiff, P.J., Cheson, B.D., Gospodarowicz, M., Advani, R., Kahl, B.S., Friedberg, J.W., Blum, K.A., Habermann, T.M., Tuscano, J.M., Hoppe, R.T. & Horning, S.J. (2012) Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology. Epub ahead of print, doi: 10.1200/JCO.2012.43.4803.
  • Gray, R. (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics, 16, 11401154.
  • Guinee, V.F., Giacco, G.G., Durand, M., van den Blink, J.W., Gustavsson, A., McVie, J.G., Zewuster, R., Dische, S., Fahey, T. & Lane, W. (1991) The prognosis of Hodgkin's disease in older adults. Journal of Clinical Oncology, 9, 947953.
  • Keegan, T.H., Glaser, S.L., Clarke, C.A., Gulley, M.L., Craig, F.E., Digiuseppe, J.A., Dorfman, R.F., Mann, R.B. & Ambinder, R.F. (2005) Epstein–Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. Journal of Clinical Oncology, 23, 76047613.
  • Kim, H.T. (2007) Cumulative incidence in competing risks data and competing risks regression analysis. Clinical Cancer Research, 13, 559565.
  • Klimm, B., Diehl, V. & Engert, A. (2007) Hodgkin's lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park), 21, 982990; discussion 990, 996, 998 passim.
  • Landgren, O., Algernon, C., Axdorph, U., Nilsson, B., Wedelin, C., Porwit-MacDonald, A., Grimfors, G. & Bjorkholm, M. (2003) Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica, 88, 438444.
  • Levis, A., Depaoli, L., Urgesi, A., Bertini, M., Orsucci, L., Vitolo, U., Buchi, G., Gallamini, A., Gavarotti, P., Novarino, A., Scalabrini, D.R., Mazza, U., Pileri, A., Sannazzari, G.L. & Resegotti, L. (1994) Probability of cure in elderly Hodgkin's disease patients. Haematologica, 79, 4654.
  • Levis, A., Depaoli, L., Bertini, M., Botto, B., Ciravegna, G., Freilone, R., Gallamini, A., Gavarotti, P., Ricardi, U., Scalabrini, D.R., Salomone, A., Salvi, F., Vitolo, U., Pileri, A., Sannazzari, G.L. & Resegotti, L. (1996) Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica, 81, 450456.
  • Martin, W.G., Ristow, K.M., Habermann, T.M., Colgan, J.P., Witzig, T.E. & Ansell, S.M. (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 76147620.
  • Mir, R., Anderson, J., Strauchen, J., Nissen, N.I., Cooper, M.R., Rafla, S., Canellos, G.P., Bloomfield, C.D., Gottlieb, A.J., Peterson, B. & Barcos, M. (1993) Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer, 71, 18571866.
  • Proctor, S.J., Wilkinson, J., Jones, G., Watson, G.C., Lucraft, H.H., Mainou-Fowler, T., Culligan, D., Galloway, M.J., Wood, K.M., McNally, R.J., James, P.W. & Goodlad, J.R. (2012) Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood, 119, 60056015.
  • Roy, P., Vaughan Hudson, G., Vaughan Hudson, B., Esteve, J. & Swerdlow, A.J. (2000) Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries. European Journal of Cancer, 36, 384389.
  • Sleijfer, S. (2001) Bleomycin-induced pneumonitis. Chest, 120, 617624.
  • Stark, G.L., Wood, K.M., Jack, F., Angus, B., Proctor, S.J. & Taylor, P.R. (2002) Hodgkin's disease in the elderly: a population-based study. British Journal of Haematology, 119, 432440.
  • Weekes, C.D., Vose, J.M., Lynch, J.C., Weisenburger, D.D., Bierman, P.J., Greiner, T., Bociek, G., Enke, C., Bast, M., Chan, W.C. & Armitage, J.O. (2002) Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. Journal of Clinical Oncology, 20, 10871093.
  • Yarnold, J.R., Jelliffe, A.M. & Hudson, G.V. (1982) Factors affecting relapse following chemotherapy for Hodgkin's disease. Clinical Radiology, 33, 627629.